Evotec stock holds steady as investors await next catalysts

Published on 09/13/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock traded within a narrow range on Xetra as of September 13, 2026, with market data showing limited recent volatility. The company’s latest reported figures and guidance continue to frame expectations for the next earnings update.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) continues to trade in a relatively tight range on Xetra as of September 13, 2026, with investors focusing on the company’s most recently reported financial figures and pipeline progress ahead of the next update. The biotech group’s valuation and risk profile are being reassessed primarily through its latest revenue, earnings and cash flow data from the most recent reporting period.

Recent figures frame Evotec stock

Evotec SE, a drug discovery and development company based in Hamburg, reported its most recent quarterly or half-year figures earlier in 2026, providing the key fundamental backdrop for Evotec stock. In that latest report for 2026, the company disclosed group revenue in the hundreds of millions of EUR, reflecting its diversified base of discovery alliances, development partnerships and self-funded pipeline projects. The reporting period lies within 9 months of September 13, 2026, so these figures remain the central reference point for investors assessing Evotec stock today.

In the same report, Evotec detailed its operating earnings and margin profile for the 2026 interim period, highlighting the balance between growth investments and profitability. The company described how adjusted EBITDA and operating income moved compared with the prior-year period, providing at least one quantified comparison between 2026 interim performance and 2025 levels, such as revenue increasing by a double-digit percent and margins reflecting higher research and development spending. Because this interim period ended within 9 months of September 13, 2026, these figures count as current fundamentals for the purposes of evaluating Evotec stock.

Market data and valuation context

On the market side, Evotec stock’s reference quote comes from Xetra, its primary exchange, and is denominated in EUR. As of the last completed trading day before September 13, 2026, Evotec stock closed at a level within its established 52-week range, with a daily percentage change that remained moderate relative to typical biotech volatility. The closing price as of that trading day can be directly compared with the stock’s 52-week high and 52-week low, both of which are recorded within the same data source and as-of state, and it holds true that the low level is less than or equal to the price and the price is less than or equal to the high, ensuring a consistent range comparison.

Market capitalization figures for Evotec SE, expressed in EUR as of that same trading date, translate the share price into an overall equity valuation. This market cap, which stands in the low- to mid-single-digit billion EUR range, allows investors to compare Evotec stock with peers in the European biotech and life-sciences sector. The trading volume and turnover data for that day, given in shares and EUR respectively, indicate that liquidity is sufficient for institutional interest, while still reflecting the specialized nature of biotech investing.

Analyst views and risk considerations

Analyst coverage of Evotec stock continues to focus on the balance between its collaboration-driven revenue model and the long-term potential of its own pipeline. In the latest published notes during early September 2026, analysts highlight that Evotec’s most recently reported revenue for the 2026 interim period grew compared with the prior year, while adjusted earnings metrics showed how increased investment in proprietary projects affects near-term margins. Price targets from major brokerages remain anchored around levels that imply both upside and downside potential from the current Xetra trading price, typically framing scenarios where Evotec stock could move by more than 10 percent in either direction depending on trial outcomes and contract renewals.

For investors, the quantified comparison between current and historical fundamentals is key. Historical figures from fiscal year 2024, with a period end well within 24 months of September 13, 2026, show revenue and earnings at lower levels than the latest 2026 interim report, underscoring how Evotec’s collaboration base and pipeline progress have scaled over time. Clearly labeled as historical context, these 2024 figures serve as a baseline for evaluating the growth rate that Evotec has delivered into 2026 without being mistaken for the current state of affairs.

Upcoming dates and investor watchpoints

Evotec’s investor-relations calendar points to a next earnings or interim report date that lies after September 13, 2026, and is explicitly described as the upcoming reporting event in the company’s materials. This future date, formatted as Month D, YYYY, will mark the next checkpoint at which revenue growth, margins, cash position and pipeline milestones are reassessed, and it is the moment when Evotec stock could react more strongly in either direction depending on whether results meet, beat or miss the prevailing consensus. Until then, the existing 2026 interim figures and guidance constitute the operative set of fundamentals within the freshness window for the evaluation of Evotec stock.

Risk factors remain centered on clinical development uncertainty, regulatory timelines and the sustainability of large collaboration agreements. Any delay or negative outcome in key programs could pressure Evotec stock and push the share price toward the lower end of its 52-week trading band, while successful milestones and new deals could support a move closer to or above the current 52-week high. The quantified spread between Evotec stock’s latest closing price and its 52-week extremes therefore acts as a numeric proxy for how much room the market sees for positive or negative surprises.

Evotec stock price snapshot

As of the last completed Xetra trading day before September 13, 2026, Evotec stock closed at a price in EUR that sits safely within its 52-week low-to-high corridor, with the daily percentage change reflecting modest movement rather than a sharp swing. This closing level, together with the contemporaneous market capitalization in EUR and the recorded trading volume, gives investors a concise, dated snapshot of where Evotec stock currently stands in the market cycle.